UNLOXCYT (cosibelimab-ipdl) is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (“cSCC”) or locally advanced cSCC who are not candidates for curative surgery or ...
and urinary tract infection. Please see full Prescribing Information. Checkpoint Therapeutics, Inc. ("Checkpoint") is a commercial-stage immunotherapy and targeted oncology company focused on the ...